Cipla Limited reported robust financial results for Q4 FY26, capping a milestone year with its 90th anniversary. The company achieved INR 28,163 crore in annual revenue, supported by significant performance in its India business, which surpassed INR 12,500 crore, and strategic growth in North America and EMEU. With strong EBITDA margins of 21% for the year and a clear focus on complex generics and innovation, Cipla is well-positioned for sustainable growth in FY27.
Financial Highlights
Cipla delivered a solid financial performance for the year ending March 31, 2026. The company reported a quarterly revenue of INR 6,541 crore, bringing the total annual revenue to INR 28,163 crore. EBITDA margins for the quarter stood at 15.2%, with the full-year margin reaching 21%. The Profit After Tax (PAT) for the year was INR 3,879 crore, representing 13.8% of sales, underscoring the firm’s operational efficiency.
Strategic Business Performance
The One India business remains the company’s largest franchise, growing 9% annually and crossing the INR 12,500 crore revenue threshold. The branded prescription business saw strong double-digit growth, led by key chronic therapies including Respiratory, Anti-diabetes, Cardiac, and Urology. Notably, the leading inhalation brand Foracort surpassed INR 1,000 crore in revenue.
In North America, the company reported an annual revenue of $780 million. A major strategic milestone was achieved with the regulatory approval for the first AB-rated generic Ventolin from the U.S. facility. Cipla aims to reach a $1 billion run rate in the U.S. by the end of FY27, supported by a pipeline of 40 to 50 products to be filed over the next three years.
Future Outlook and Innovation
Cipla is aggressively pursuing an AI-led transformation to enhance manufacturing efficiency and R&D decision-making. The company is committed to complex generics, including peptides, oligonucleotides, and biosimilars. With a robust pipeline of over 17 new product launches planned for the domestic market and several respiratory assets in the U.S. pipeline, management maintains a positive growth trajectory. For FY27, the company projects EBITDA margins in the range of 18.5% to 20%, with expected sequential improvements through the year.
Source: BSE
